Clinical Trials
71 trialsInotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
ACCESS
Center for International Blood and Marrow Transplant Research
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Weill Medical College of Cornell University
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
City of Hope Medical Center
Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma
University of Nebraska
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma
University of Nebraska
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Nebraska
Autologous Transplant in HIV Patients (BMT CTN 0803)
Medical College of Wisconsin
BMT CTN 0903
Medical College of Wisconsin
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
St. Jude Children's Research Hospital
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
M.D. Anderson Cancer Center
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
M.D. Anderson Cancer Center
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
M.D. Anderson Cancer Center
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
St. Jude Children's Research Hospital
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
M.D. Anderson Cancer Center
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
University of Maryland, Baltimore
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
University of Maryland, Baltimore
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
ALBUM
University of Arizona
Reduced Intensity Double Umbilical Cord Blood Transplantation
Massachusetts General Hospital
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
New York Medical College
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
Weill Medical College of Cornell University
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
ZBEAM2
Lymphoma Study Association
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
SWOG Cancer Research Network
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
OHSU Knight Cancer Institute
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
M.D. Anderson Cancer Center
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
University of Chicago
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies
M.D. Anderson Cancer Center
Z-BEAM LDGGB
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
Memorial Sloan Kettering Cancer Center
Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
MAC UCBT
University College, London
S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia
SWOG Cancer Research Network
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
SWOG Cancer Research Network
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
National Cancer Institute (NCI)
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
National Cancer Institute (NCI)
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
National Cancer Institute (NCI)
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center